Publications by authors named "Derek Lamb"

Article Synopsis
  • Primaquine and Tafenoquine are the only drugs that can cure malaria completely, but they pose risks for individuals with G6PD deficiency, potentially causing severe blood cell damage.
  • The study introduces a new mouse model replicating a specific human G6PD variant, allowing researchers to observe how a metabolite called 5,6-POQ affects red blood cells.
  • The research indicates that 5,6-POQ is not just a harmless byproduct of drug metabolism but actively contributes to the destruction of older red blood cells in G6PD-deficient individuals, challenging previous assumptions about its role.
View Article and Find Full Text PDF

Normothermic ex vivo lung perfusion (EVLP) can resuscitate marginal lung allografts to increase organs available for transplantation. During normothermic perfusion, cellular metabolism is more active compared with subnormothermic perfusion, creating a need for an oxygen (O 2 ) carrier in the perfusate. As an O 2 carrier, red blood cells (RBCs) are a scarce resource and are susceptible to hemolysis in perfusion circuits, thus releasing cell-free hemoglobin (Hb), which can extravasate into the tissue space, thus promoting scavenging of nitric oxide (NO) and oxidative tissue damage.

View Article and Find Full Text PDF

Polymerized human hemoglobin (PolyhHb) has shown promise in preclinical hemorrhagic shock settings. Different synthetic and purification schemes can control the size of PolyhHbs, yet research is lacking on the impact of polymerized hemoglobin size on tissue oxygenation following hemorrhage and resuscitation in specialized animal models that challenge their resuscitative capabilities. Pre-existing conditions that compromise the vasculature and end organs, such as the liver, may limit the effectiveness of resuscitation and exacerbate the toxicity of these molecules, which is an important but minimally explored therapeutic dimension.

View Article and Find Full Text PDF

Aberrant coagulation in sickle cell disease (SCD) is linked to extracellular vesicle (EV) exposure. However, there is no consensus on the contributions of small EVs (SEVs) and large EVs (LEVs) toward underlying coagulopathy or on their molecular cargo. The present observational study compared the thrombin potential of SEVs and LEVs isolated from the plasma of stable pediatric and adult SCD patients.

View Article and Find Full Text PDF

Red blood cell (RBC) substitutes tested in late-phase clinical trials contained low-molecular-weight hemoglobin species (<500 kDa), resulting in vasoconstriction, hypertension, and oxidative tissue injury; therefore, contributing to poor clinical outcomes. This work aims to improve the safety profile of the RBC substitute, polymerized human hemoglobin (PolyhHb), via in vitro and in vivo screening of PolyhHb fractionated into four molecular weight brackets (50-300 kDa [PolyhHb-B1]; 100-500 kDa [PolyhHb-B2]; 500-750 kDa [PolyhHb-B3]; and 750 kDa to 0.2 μm [PolyhHb-B4]) using a two-stage tangential flow filtration purification process.

View Article and Find Full Text PDF

Extracellular vesicles (EVs) participate in cell-to-cell communication and contribute toward homeostasis under physiological conditions. But EVs can also contribute toward a wide array of pathophysiology like cancer, sepsis, sickle cell disease, and thrombotic disorders. COVID-19 infected patients are at an increased risk of aberrant coagulation, consistent with elevated circulating levels of ultra-high molecular weight VWF multimers, D-dimer and procoagulant EVs.

View Article and Find Full Text PDF

Importance: Maximizing benefits of lung cancer screening requires timely follow-up after a positive screening test. The American College of Radiology (ACR) Lung CT Screening Reporting and Data System (Lung-RADS) recommends testing and follow-up timing based on the screening result.

Objective: To determine rates of and factors associated with recommended follow-up after a positive lung cancer screening examination by Lung-RADS category.

View Article and Find Full Text PDF
Article Synopsis
  • Individuals with lung-related comorbidities may experience different outcomes in lung cancer screening, impacting the benefits and harms identified during the process.
  • A study analyzed data from 611 participants in North Carolina, revealing that 54.8% had at least one lung-related comorbidity, with notable demographic differences between those who did and did not—such as gender, race, and education level.
  • Despite these differences, the study found no significant variation in the rates of positive lung cancer screening results based on the presence of comorbidities.
View Article and Find Full Text PDF

Purpose: To assess immunohistologic features of angiogenesis of T1N0M0 oral squamous cell carcinoma (OSCC), and to identify predictors of regional recurrence. The identification of prognostic markers of early lymph node involvement in OSCC could allow for the use of more targeted biologic therapies for patients with early-stage tumors.

Patients And Methods: The study included patients treated for T1N0M0 OSCC at the Mayo Clinic from 1986 to 2001.

View Article and Find Full Text PDF